Thus, the APP/PS1 transgenic mouse model is quite suitable for observing the effects of AD preventive drugs on the elevation of amyloid and its consequences, whether as initiating events or key elements facilitating AD progress in the early stages of AD 4, 18, 19, 41. This evidence concerns the gene APP and Alzheimer disease.